We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




World’s Most Comprehensive Whole Genome Sequencing Solution Diagnoses Rare and Neurodegenerative Diseases

By LabMedica International staff writers
Posted on 13 Apr 2023

Diagnosing rare and neurodegenerative diseases can be challenging, even for experienced physicians. More...

Patients often endure a diagnostic journey that spans years and multiple misdiagnoses before receiving an accurate diagnosis. Now, the world’s most comprehensive whole genome sequencing solution for rare and neurodegenerative diseases integrates state-of-the-art technology and an efficient CE-IVD bioinformatics pipeline with a vast biodatabank of around 700,000 patients from over 120 diverse countries. This approach can significantly save time and resources by eliminating the need for stepwise testing, allowing healthcare professionals to deliver quick and reliable diagnoses and identify treatment options.

Centogene N.V. (Rostock, Germany) has introduced NEW CentoGenome, an advanced Next Generation Sequencing (NGS)-based assay. With NEW CentoGenome, healthcare professionals can offer more comprehensive diagnostic information, potentially accelerating access to treatment options. As a first-line test, NEW CentoGenome is the most extensive commercially available Whole Genome Sequencing (WGS) test for both rare and neurodegenerative disorders. It covers nearly all disease-causing variants, including the most relevant repeat expansions linked to neurological diseases, in a single assay. NEW CentoGenome also detects Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA) and complex disease-causing variants related to Gaucher Disease (GD) and susceptibility to GBA1-related Parkinson's Disease (PD), with exceptional sensitivity.

The newly-designed WGS assay utilizes a Polymerase Chain Reaction (PCR)-free approach, significantly reducing the typical bias induced by PCR and offering higher quality sequencing data across challenging genome regions. This is achieved by enabling more uniform coverage and superior performance in variant detection. The assay's superior performance is supported by CENTOGENE's automated CE-IVD bioinformatics pipeline and medical expert-based analysis of the CENTOGENE Biodatabank, which comprises approximately 700,000 patients from over 120 highly diverse countries.

“As a pioneer of genetic diagnostics, we are committed to enabling access to high-quality diagnostics and ensuring that cutting-edge data analyses are available to support better patient health outcomes,” said Prof. Peter Bauer, Chief Medical and Genomic Officer at CENTOGENE. “Building on this expertise, CENTOGENE’s enhanced whole genome sequencing is the leading solution on the market, reflecting the latest advanced technologies and unique insights that can’t be found anywhere else to provide maximized disease coverage. Ultimately, this will provide physicians with an unparalleled level of certainty when diagnosing, prognosing, and treating patients.”

Related Links:
Centogene N.V.


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.